| 熊 伟,张 莉,董 科,古 春,俞小炯.恩替卡韦联合聚乙二醇干扰素α-2b治疗HBeAg阳性乙肝的临床研究[J].现代生物医学进展英文版,2019,19(6):1091-1094. |
| 恩替卡韦联合聚乙二醇干扰素α-2b治疗HBeAg阳性乙肝的临床研究 |
| Clinical Study of Entecavir Combined with Peginterferon α -2b in the Treatment of HBeAg Positive Hepatitis B |
| Received:August 10, 2018 Revised:August 31, 2018 |
| DOI：10.13241/j.cnki.pmb.2019.06.019 |
| 中文关键词: 恩替卡韦 聚乙二醇干扰素α-2b HBeAg阳性 乙肝 血清学转换 转阴率 安全性 |
| 英文关键词: Entecavir Peginterferon α-2b HBeAg-positive Hepatitis B Serological conversion Seroconversion rate Safety |
| 基金项目:四川省卫生厅科研基金项目（30520010065） |
| Author Name | Affiliation | E-mail | | XIONG Wei | Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, China | xiwoqu@163.com | | ZHANG Li | Department of Elderly Gastroenterology, Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, China | | | DONG Ke | Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, China | | | GU Chun | Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, China | | | YU Xiao-jiong | Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, China | |
|
| Hits: 921 |
| Download times: 556 |
| 中文摘要: |
| 摘要 目的：探讨恩替卡韦联合聚乙二醇干扰素α-2b治疗乙型肝炎E抗原（HBeAg）阳性乙肝的临床疗效、安全性及对相关标志物的影响。方法：选取2015年10月至2017年10月我院收治的97例HBeAg阳性乙肝患者，采用随机数字表法将其分为对照组48例和观察组49例。对照组患者采用单纯皮下注射聚乙二醇干扰素α-2b注射剂治疗，观察组采用恩替卡韦联合聚乙二醇干扰素α-2b治疗。比较两组患者治疗后的临床疗效、谷草转氨酶（AST）、丙氨酸转氨酶（ALT）、乙肝病毒的脱氧核糖核酸（HBV-DNA）含量以及ALT复常率、HBeAg血清转换率、HBV-DNA转阴率及不良反应发生率。结果：观察组总治疗有效率为91.84%，明显高于对照组的77.55%( P<0.05)；治疗后，观察组的ALT、AST、HBV-DNA含量明显低于对照组(P<0.05)，观察组的ALT复常率、HBeAg血清学转换率、HBV-DNA转阴率明显高于对照组(P<0.05)；观察组治疗期间不良反应发生率为30.61%，与对照组的29.17%比较差异无统计学意义(P>0.05)。结论：恩替卡韦联合聚乙二醇干扰素α-2b治疗HBeAg阳性乙肝较单用干扰素的抗病毒治疗疗效更高，可降低传染性，用药安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the the clinical efficacy, safety and effects of entecavir combined with peginterferon α-2b in the treatment of hepatitis B E antigen (HBeAg) positive hepatitis B. Methods: 97 cases of HBeAg positive hepatitis B patients enrolled in our hospital from October 2015 to October 2017 were divided into control group (n=48) and observation group (n=49) by random number table methods. The control group was treated with subcutaneous injection of peginterferon α-2b, while the observation group was treated with entecavir combined with peginterferon alpha-2b. The clinical efficacy, the content of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and hepatitis B virus DNA (HBV-DNA), the conversion rate of HBeAg serological, the seroconversion rate of hepatitis B virus deoxyribonucleic acid (HBV-DNA), and the incidence of adverse reactions of the patients in the two groups after treatment was compared. Results: The total effective rate of observation group was 91.84%, which was significantly higher than that of control group (x2=8.50, P<0.05). After treatment, the contents of ALT, AST and HBV-DNA in observation group was significantly lower than those in control group(P<0.05), the repetition rate of ALT, the conversion rate of HBeAg serological,the seroconversion rate of HBV-DNA rate was significantly higher than those of the control group (P<0.05). After treatment, the incidence of adverse reactions in the observation group was 30.61%, compared with 29.17% in the control group, the difference was not statistically significant (P>0.05). Conclusion: The efficacy of entecavir combined with peginterferon α-2b in the treatment of HBeAg positive hepatitis B is better than that of interferon alone, it can reduce the contagiousness and has a good safty. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
